Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.

Trial Details

NCT ID

NCT04288999

Phase

PHASE3

Sponsor

National Cancer Center Hospital East

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Chemotherapy
Preoperative radiotherapy
Procedure

Locations (sample)

Chiba, Japan|35.6,140.11667
Gifu, Japan|35.42291,136.76039
Hidaka, Japan|35.91664,139.36233
Hirakata, Japan|34.81352,135.64914
Hiroshima, Japan|34.4,132.45

Key Eligibility Criteria

Histopathologically proven adenocarcinoma or adenosquamous carcinoma on the resected specimen of the initial rectal cancer or endoscopic biopsy fro…
The main tumor location of the initial rectal cancer is upper, middle or lower rectum, or anal canal.
Either of the following treatments was performed for the initial rectal cancer, and classified as R0/1 or ER (Endoscopical R)0/1 on pathological di…
i) Surgical resection (including local resection, with or without lymph node dissection).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →